Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.46 USD
+0.03 (2.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.47 +0.01 (0.68%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Income Statements
Fiscal Year end for Spero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 104 | 54 | 18 | 9 | 18 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 104 | 54 | 18 | 9 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 82 | 96 | 106 | 88 | 81 |
Income After Depreciation & Amortization | 21 | -42 | -88 | -79 | -63 |
Non-Operating Income | 4 | -2 | 0 | 1 | 2 |
Interest Expense | 0 | 3 | 2 | 0 | 0 |
Pretax Income | 25 | -46 | -90 | -78 | -61 |
Income Taxes | 3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 23 | -46 | -90 | -78 | -61 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 23 | -46 | -90 | -78 | -61 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 22 | -41 | -87 | -78 | -62 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | 21 | -42 | -88 | -79 | -63 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 52.99 | 37.59 | 30.90 | 22.39 | 18.16 |
Diluted EPS Before Non-Recurring Items | 0.51 | -1.23 | -2.91 | -3.52 | -3.35 |
Diluted Net EPS (GAAP) | 0.43 | -1.23 | -2.91 | -3.52 | -3.35 |
Fiscal Year end for Spero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 73.52 | 25.47 | 2.72 | 2.07 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 73.52 | 25.47 | 2.72 | 2.07 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.99 | 27.40 | 15.61 | 16.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 50.53 | -1.93 | -12.89 | -14.23 |
Non-Operating Income | NA | 1.05 | 0.94 | 0.98 | 0.96 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 51.58 | -0.99 | -11.91 | -13.27 |
Income Taxes | NA | 0.39 | 2.21 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 51.19 | -3.21 | -11.91 | -13.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 51.19 | -3.21 | -11.91 | -13.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 53.11 | 52.71 | 52.57 | 52.53 |
Diluted EPS Before Non-Recurring Items | NA | 0.96 | 0.02 | -0.23 | -0.25 |
Diluted Net EPS (GAAP) | NA | 0.97 | -0.06 | -0.23 | -0.25 |